Early Breast Cancer: A New Look at Radiation

Can Some Women With Early Breast Cancer Safely Skip Radiation?

Can Some Women With Early Breast Cancer Safely Skip Radiation? Radiation therapy after a lumpectomy has been a standard part of breast-conserving treatment for decades. And for good reason. Radiation can significantly reduce the risk that breast cancer will return in the treated breast.

But an important question has emerged from decades of clinical research:

Does every woman with early-stage breast cancer need radiation after a lumpectomy?

For some carefully selected women—particularly older women with small, lymph-node-negative, hormone-receptor-positive tumors who receive endocrine therapy—the answer may be no.

Long-term randomized trials have shown an important distinction:

Radiation can substantially reduce local breast cancer recurrence without necessarily improving overall survival in these low-risk patients.

That does not mean radiation is ineffective.

It means that the potential benefit of radiation depends heavily on the individual patient’s age, tumor biology, stage, recurrence risk, life expectancy, other medical conditions, and willingness to take endocrine therapy.

For a broader discussion of how radiation is used today, read:

Radiation for Breast Cancer: What Patients Need to Know

I am a long-term survivor of an incurable blood cancer called multiple myeloma. My research and experience with evidence-based non-conventional therapies are the reason why I have lived in complete remission from my incurable blood cancer since achieving complete remission in early 1999. I have learned that the best way to manage cancer is to combine the best of conventional and evidence-based non-conventional therapies.

Scroll down the page and post a question or a comment if there’s anything you’d like to know about breast cancer.

Good luck,

David Emerson

Concepts Central to Managing Your Cancer-

Possible Therapies

Radiation After Lumpectomy: What Does It Actually Accomplish?

A lumpectomy removes the visible tumor while preserving most of the breast. Microscopic cancer cells, however, can remain in the breast after surgery.

Radiation therapy is designed to destroy these remaining cells and reduce the risk of cancer returning in or near the treated breast.

Across women with early breast cancer as a whole, the evidence supporting radiation after breast-conserving surgery is strong.

A major meta-analysis from the Early Breast Cancer Trialists’ Collaborative Group involving 10,801 women in 17 randomized trials found that radiation after breast-conserving surgery reduced both breast cancer recurrence and, over longer follow-up, breast cancer mortality.

Research: Radiotherapy After Breast-Conserving Surgery — EBCTCG/Lancet

Therefore, the conclusion should not be:

Radiation doesn’t improve survival in early breast cancer.

The more accurate question is:

Are there identifiable groups of women whose risk of recurrence is already so low that the additional benefit of radiation may not justify its inconvenience, cost, and potential short- and long-term side effects?

Increasingly, research suggests that there are.

CALGB 9343: Radiation Reduced Recurrence but Did Not Improve Overall Survival

One of the most important studies addressing this question is the randomized CALGB 9343 trial.

The study included 636 women who were:

Age 70 or older
Diagnosed with stage I breast cancer
Estrogen-receptor (ER) positive
Clinically lymph-node negative
Treated with lumpectomy
Treated with tamoxifen

The women were randomly assigned to:

Tamoxifen + radiation

Tamoxifen alone

The long-term results are remarkably useful for patients making treatment decisions.

At 10 years:

Outcome	Tamoxifen + Radiation	Tamoxifen Alone
Free from local/regional recurrence	98%	90%
Overall survival	67%	66%

Radiation therefore produced an approximately 8 percentage-point improvement in local/regional cancer control.

But overall survival was essentially identical.

The investigators also found no significant difference in distant metastasis, breast cancer-specific survival, or the probability of eventually requiring mastectomy.

Research: Long-Term Follow-Up of CALGB 9343

This is the central risk-benefit issue.

Radiation clearly did something important—it reduced recurrence.

But among these carefully selected older women, that improvement did not translate into longer overall survival.

PRIME II Confirmed the Same Basic Finding

A second major randomized trial, PRIME II, extended this question to women age 65 and older. The study included women with low-risk, hormone-receptor-positive early breast cancer who underwent breast-conserving surgery and received endocrine therapy.

After 10 years, local breast cancer recurrence was substantially different:

9.5% without radiation
0.9% with radiation

That is a meaningful reduction in recurrence. But overall survival was essentially identical:

80.8% without radiation
80.7% with radiation

Breast cancer-specific survival was also very similar.

Research: Breast-Conserving Surgery With or Without Irradiation — PRIME II

Again, radiation worked.

The question is what outcome matters most to the individual patient?

For one woman, reducing a roughly 10% long-term local recurrence risk to about 1% may make radiation clearly worthwhile.

Another woman—particularly one with significant health problems or concerns about treatment burden—may reasonably place greater weight on avoiding radiation when the available evidence suggests no overall-survival difference for patients resembling those studied.

That is a decision to make with the breast surgeon, medical oncologist, and radiation oncologist.

LUMINA: Can Tumor Biology Help Identify Women Who Need Even Less Treatment?

Age and tumor size are no longer the only ways to estimate recurrence risk. Modern breast cancer treatment increasingly considers tumor biology.

The prospective LUMINA study investigated whether women with especially favorable luminal A breast cancers could omit radiation following breast-conserving surgery.

Women were at least 55 years old and had:

T1N0 breast cancer
Grade 1 or 2 disease
Luminal A tumor biology
ER-positive disease
PR expression greater than 20%
HER2-negative disease
Low Ki-67 proliferation
Endocrine therapy

Radiation was omitted.

At five years, the reported local recurrence rate was approximately 2.3%.

Research: Omitting Radiotherapy After Breast-Conserving Surgery in Luminal A Breast Cancer — LUMINA

LUMINA was not a randomized comparison of radiation versus no radiation, and its follow-up is shorter than CALGB 9343 or PRIME II.

Still, it illustrates where breast cancer treatment is heading:

Treatment decisions increasingly depend not simply on the size of a tumor, but on its biology and its estimated risk of recurrence.

Who Might Be Able to Consider Skipping Radiation?

Radiation omission should not be generalized to everyone with early-stage breast cancer.

The strongest long-term randomized evidence applies primarily to older women with favorable cancers.

Characteristics that may prompt a discussion about radiation omission include:

Older age
Small invasive tumor
Negative lymph nodes
Clear surgical margins
Estrogen-receptor-positive disease
HER2-negative disease
Low tumor grade
Favorable tumor biology
Planned endocrine therapy
Limited competing risk of aggressive breast cancer
Medical conditions that increase the burden or risk of radiation

The decision becomes much different in a younger patient or someone with:

Positive lymph nodes
Large tumor
Positive margins
Triple-negative breast cancer
HER2-positive disease requiring appropriate systemic treatment
High-grade disease
Lymphovascular invasion
Other features associated with increased recurrence risk

Radiation may provide substantially greater benefit in these situations.

Radiation Omission Is Not the Same as Doing Nothing

This distinction is extremely important. The women in CALGB 9343 and PRIME II weren’t simply treated with lumpectomy and sent home. They received endocrine therapy.

In hormone-receptor-positive breast cancer, treatments such as tamoxifen or aromatase inhibitors reduce recurrence risk.

Therefore, a patient considering radiation omission should ask:

How important is endocrine therapy to the safety of this strategy?

The answer may be very important.

If you are unlikely or unable to remain on endocrine therapy because of side effects, your recurrence risk may differ from the women represented in these trials.

Treatment decisions should consider the entire treatment plan rather than evaluating radiation in isolation.

What About Partial-Breast Radiation?

The decision is no longer necessarily:

whole-breast radiation versus no radiation.

A third possibility is partial-breast irradiation. Rather than irradiating the entire breast, partial-breast radiation targets the region surrounding the original tumor.

Current ASTRO guidance supports partial-breast irradiation as an alternative to whole-breast radiation for appropriately selected patients with early-stage, node-negative invasive breast cancer and certain patients with DCIS. Favorable characteristics include factors such as small tumor size, ER-positive disease and lower-grade cancer.

ASTRO Guideline: Partial-Breast Irradiation for Early-Stage Breast Cancer

This matters because a woman who wants additional protection against local recurrence but wants to minimize treatment burden may have options besides traditional whole-breast radiation.

Modern radiation schedules can also be dramatically shorter than they were years ago.

Read:

Radiation for Breast Cancer: What Patients Need to Know

What Are the Potential Downsides of Breast Radiation?

Modern breast radiation is safer and more precisely targeted than radiation delivered decades ago. Nevertheless, radiation is not biologically free.

Possible short-term effects include:

Fatigue
Skin irritation
Breast swelling
Tenderness
Skin discoloration

Possible long-term or late effects can include:

Breast fibrosis or firmness
Persistent skin or tissue changes
Lymphedema
Chronic pain
Lung injury
Cardiovascular effects, particularly depending on cardiac radiation exposure
Rare rib injury
Rare secondary cancers

For more about long-term breast cancer treatment effects, see:

Life After Breast Cancer: Long-Term Side Effects and Survivorship

For pain associated with surgery, radiation, and other breast cancer treatments:

Breast Cancer and Pain: What Patients and Survivors Need to Know

Radiation-associated angiosarcoma is an especially rare but recognized late complication:

Radiation for Breast Cancer: The Risk of Angiosarcoma Is Real

These risks should be placed in context. For many women, the absolute benefits of radiation substantially outweigh its risks.

The question is whether that is true for you.

The Most Important Number May Be Your Absolute Benefit

Cancer patients frequently hear statements such as:

“Radiation cuts your recurrence risk dramatically.”

That can be true while still failing to tell the patient what she most needs to know.

Consider PRIME II.

Radiation reduced the 10-year local recurrence rate from approximately 9.5% to 0.9%.

That’s a large relative reduction.

But the absolute difference was approximately 8.6 percentage points.

At the same time, 10-year overall survival was essentially unchanged.

Neither statistic should be considered in isolation.

A useful conversation with a radiation oncologist therefore might begin with:

“For someone with my exact tumor characteristics, what is my absolute risk of recurrence with radiation and without radiation—and is radiation expected to change my breast cancer-specific or overall survival?”

That question turns a general treatment recommendation into an individualized risk-benefit discussion.

What About Radiation After Mastectomy?

This article focuses primarily on radiation after breast-conserving surgery.

Radiation after mastectomy is a different clinical question.

The updated 2025 ASTRO/ASCO/SSO guideline recommends post-mastectomy radiation for many patients with node-positive disease and certain other higher-risk cancers. Conversely, post-mastectomy radiation is generally not recommended for patients with pT1-2, node-negative disease unless multiple unfavorable characteristics substantially increase recurrence risk.

ASTRO/ASCO/SSO Post-Mastectomy Radiation Guideline

So the evidence discussed in CALGB 9343 and PRIME II should not be interpreted as evidence that radiation is unnecessary for breast cancer generally.

Questions to Ask Your Radiation Oncologist

If you have early-stage breast cancer, consider asking:

What is my exact stage, grade, ER/PR status and HER2 status?
Are my lymph nodes negative?
Are my surgical margins clear?
What is my estimated 5-year and 10-year local recurrence risk without radiation?
What would that risk be with radiation?
Does radiation improve my breast cancer-specific survival?
Does radiation improve my overall survival?
Am I similar to the women enrolled in CALGB 9343 or PRIME II?
Is my tumor biology favorable enough to consider radiation omission?
How important is endocrine therapy if I skip radiation?
Am I a candidate for partial-breast radiation?
Could I receive a shorter hypofractionated radiation schedule?
What are my personal short- and long-term risks from radiation?
How much radiation would my heart and lungs receive?
What happens if I choose not to undergo radiation and the cancer returns locally?

PeopleBeatingCancer Evidence Rating

Radiation after breast-conserving surgery reduces local recurrence

Evidence Rating: STRONG

Multiple randomized trials and large meta-analyses demonstrate that radiation reduces ipsilateral breast and locoregional recurrence following breast-conserving surgery.

Selected older women with low-risk HR-positive breast cancer may omit radiation without reducing overall survival

Evidence Rating: STRONG

CALGB 9343 and PRIME II provide long-term randomized evidence showing substantially greater local recurrence when radiation is omitted but no demonstrated overall-survival disadvantage among the carefully selected populations studied.

Tumor biology can identify additional patients who may safely omit radiation

Evidence Rating: MODERATE / EMERGING

LUMINA and other contemporary studies are encouraging, but longer follow-up and additional randomized evidence are important before applying these results broadly.

Radiation can be omitted in all early-stage breast cancers

Evidence Rating: NOT SUPPORTED

“Early breast cancer” includes biologically and clinically different diseases. Radiation decisions should be individualized according to age, stage, lymph-node involvement, surgical margins, receptor status, tumor biology, systemic treatment and recurrence risk.

The Bottom Line

The original idea behind this article remains important—but it needs an important qualification.

Radiation therapy does not simply “fail to improve survival” in early breast cancer.

Across breast cancer populations, radiation reduces recurrence and can reduce breast cancer mortality.

But randomized clinical trials have identified a subgroup of older women with favorable, hormone-receptor-positive, node-negative early breast cancer in whom radiation after lumpectomy dramatically reduces local recurrence without a demonstrated improvement in overall survival.

That distinction matters.

CALGB 9343 found that approximately 98% of women receiving radiation versus 90% of women omitting radiation remained free of local/regional recurrence at 10 years—yet overall survival was 67% versus 66%.

PRIME II reached a similar conclusion: radiation reduced 10-year local recurrence from approximately 9.5% to 0.9%, while overall survival remained virtually identical.

For some women, preventing that recurrence is easily worth undergoing radiation.

For others, particularly older women with favorable cancers, significant medical problems, treatment-burden concerns, or strong preferences to minimize therapy, radiation omission may be worth discussing.

The goal shouldn’t be to receive the most treatment possible.

Nor should it be to avoid conventional cancer therapy whenever possible.

The goal is to understand how much a treatment is likely to help you, what risks accompany it, and whether its absolute benefit justifies those risks and burdens in your individual situation.

That is what informed cancer decision-making should look like.

To Learn More about Breast Cancer:

Radiation Does Not Improve Survival in Elderly Early-Stage Breast Cancer Patients

“Adjuvant radiation therapy might not be necessary for older women with early-stage BC who undergo lumpectomy. Women 70 years or older with early-stage disease who have a lumpectomy and also receive tamoxifen can safely forego radiation therapy because it does not appear to affect survival, distant disease-free survival, breast-cancer-specific survival, or breast conservation, a new study concludes…

You can get about a 6% reduction in in-breast recurrence with the addition of radiation...and no impact on overall survival,” he said.

Delaying Post-Surgical Radiation Increases Risk of Breast Cancer Recurrence in Older Women

“Older women who have had BC surgery have a greater risk of cancer returning if they delay their post-surgical radiation treatment, report Dana-Farber Cancer Institute scientists…

The researchers reviewed Medicare database records of 18,050 women with early-stage breast cancer to assess whether the timing of when radiotherapy started following surgery affected outcomes. These women were treated between 1991 and 2002 with lumpectomy and radiation, but not chemotherapy. Thirty percent of women began radiotherapy six or more weeks after surgery…

For the overall group, slightly more than 4 percent of the women experienced a local recurrence. The risk increased to about 5 percent, approximately a 19 percent jump when the surgery-radiotherapy interval was longer than six weeks.”

Our Mission